COLUMBIA, S.C. (April 13, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose oral inhalation product, Arformoterol Tartrate (15 mcg/2 ml), making the company the largest generic drug maker of its kind. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.
Arformoterol Tartrate is the generic equivalent to the branded drug, Brovana, and is an oral inhalation used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease (COPD). COPD constitutes a group of lung diseases including chronic bronchitis and emphysema. Arformoterol Tartrate is in a class of medications called long-acting beta agonists and works by relaxing and opening air passages in the lungs, making it easier to breathe.
Ritedose’s single-dose ampules of Arformoterol Tartrate come individually wrapped and barcoded in cartons.
“We’re pleased to expand our generics portfolio,” said Ritedose President and CEO Jody Chastain. “With the launch of Arformoterol Tartrate, Ritedose now offers the most complete nebulized inhalation drug portfolio in the industry. That means we’re able to offer our clients even more of the many products they regularly need with ample, reliable supplies.”
Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and packaging of single-dose medication, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 27-year track record includes delivery of more than 10 billion doses since 2012 without interruption, and its current capacity is 2 billion units annually.